Myriad Genetics (NASDAQ:MYGN) PT Raised to $31.00 at The Gol

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective boosted by research analysts at The Goldman Sachs Group from $28.00 to $31.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of […]

Related Keywords

Canada , United States , Piper Sandler , Us Bancorp , Wolfe Research , Proshare Advisors , Nasdaq , Pricet Rowe Associates Inc , Genetics Inc , Royal Bank , Goldman Sachs Group , Ameritas Investment Partners Inc , Wells Fargo Company , Myriad Genetics , Get Free Report , Investment Partners , Share Advisors , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn , Mygn , Medical , 62855j10 , Boost Price Target , The Goldman Sachs Group Inc ,